Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen

Purpose: The idiotype (Id) of the immunoglobulin on a given B-cell malignancy is a clonal marker that can serve as a tumor-specific antigen. We developed a novel vaccine formulation by incorporating Id protein with liposomal lymphokine that was more potent than a prototype, carrier-conjugated Id protein vaccine in preclinical studies. In the present study, we evaluated the safety and immunogenicity of this vaccine in follicular lymphoma patients. Experimental Design: Ten patients with advanced-stage follicular lymphoma were treated with five doses of this second generation vaccine after chemotherapy-induced clinical remission. All patients were evaluated for cellular and humoral immune responses. Results: Autologous tumor and Id-specific type I cytokine responses were induced by vaccination in 10 and 9 patients, respectively. Antitumor immune responses were mediated by both CD4+ and CD8+ T cells, were human lymphocyte antigen class I and II associated, and persisted 18 months beyond the completion of vaccination. Specific anti-Id antibody responses were detected in four patients. After a median follow-up of 50 months, 6 of the 10 patients remain in continuous first complete remission. Conclusions: This first clinical report of a liposomal cancer vaccine demonstrates that liposomal delivery is safe, induces sustained tumor-specific CD4+ and CD8+ T-cell responses in lymphoma patients, and may serve as a model for vaccine development against other human cancers and infectious pathogens.

[1]  M. Baseler,et al.  A modified human ELISPOT assay to detect specific responses to primary tumor cell targets , 2004, Journal of Translational Medicine.

[2]  R. Elashoff,et al.  Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  A. Ribas,et al.  Determinant spreading and tumor responses after peptide-based cancer immunotherapy. , 2003, Trends in immunology.

[4]  N. Schmitz,et al.  Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte–macrophage colony‐stimulating factor and interleukin 2 in a myeloma model , 2003, British journal of haematology.

[5]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[6]  J. Schlom,et al.  Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. , 2002, Cancer research.

[7]  M. Cheever,et al.  Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Czerwinski,et al.  Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. , 2002, Blood.

[9]  R. Yañez,et al.  Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. , 2002, Haematologica.

[10]  F. Marincola,et al.  Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading , 2001, International journal of cancer.

[11]  G. Storm,et al.  Liposomes to target the lymphatics by subcutaneous administration. , 2001, Advanced drug delivery reviews.

[12]  A. Enk,et al.  A comparison of two types of dendritic cell as adjuvants for the induction of melanoma‐specific T‐cell responses in humans following intranodal injection , 2001, International journal of cancer.

[13]  D. Crommelin,et al.  Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects. , 2001, Biochimica et biophysica acta.

[14]  C. Alving,et al.  Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil. , 2000, Advanced drug delivery reviews.

[15]  J. Kirkwood,et al.  Dendritic Cell/Peptide Cancer Vaccines: Clinical Responsiveness and Epitope Spreading , 2000, Immunological investigations.

[16]  S. Jagannath,et al.  Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. , 2000, Blood.

[17]  L. Kanz,et al.  Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. , 2000, Blood.

[18]  Craig W. Reynolds,et al.  Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma , 1999, Nature Medicine.

[19]  J. Moreno,et al.  Endogenous and exogenous forms of the same antigen are processed from different pools to bind MHC class II molecules in endocytic compartments , 1999, European journal of immunology.

[20]  M. C. Popescu,et al.  Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. , 1998, Journal of immunology.

[21]  J. Gribben,et al.  Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. , 1997, Blood.

[22]  D. Czerwinski,et al.  Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. , 1997, Blood.

[23]  H. Young,et al.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[25]  J. Gribben,et al.  Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. Lechler,et al.  Endogenous pathway of class II presentation. , 1995, Biochemical Society transactions.

[27]  P. Duffey,et al.  Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor , 1995, The Lancet.

[28]  D. Papahadjopoulos,et al.  Liposomes revisited , 1995, Science.

[29]  C. Alving,et al.  Liposomes as carriers for vaccines. , 1994, ImmunoMethods.

[30]  A. Sant.  Endogenous antigen presentation by MHC class II molecules , 1994, Immunologic research.

[31]  R. Levy,et al.  Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.

[32]  L. Adorini,et al.  Processing of an endogenous protein can generate MHC class II-restricted T cell determinants distinct from those derived from exogenous antigen. , 1991, Journal of immunology.

[33]  E. Unanue,et al.  Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. , 1991, Journal of immunology.

[34]  C. Alving,et al.  Liposomes as carriers of antigens and adjuvants. , 1991, Journal of immunological methods.

[35]  E. Jaffe,et al.  Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Zelenetz,et al.  Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin. , 1990, Blood.

[37]  R. Klausner,et al.  Class II MHC molecules can use the endogenous pathway of antigen presentation , 1990, Nature.

[38]  R. Levy,et al.  Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. , 1987, Journal of immunology.

[39]  W. Carroll,et al.  Mouse x human heterohybridomas as fusion partners with human B cell tumors. , 1986, Journal of immunological methods.

[40]  V. Budker,et al.  Subcutaneously injected radiolabeled liposomes: transport to the lymph nodes in mice. , 1982, Journal of the National Cancer Institute.

[41]  F. Stevenson,et al.  Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. , 1977, Federation proceedings.

[42]  R. Williams,et al.  Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein. , 1976, Journal of the National Cancer Institute.

[43]  F. Stevenson,et al.  Antibody to a molecularly-defined antigen confined to a tumour cell surface , 1975, Nature.

[44]  H. Eisen,et al.  Myeloma proteins as tumor-specific transplantation antigens. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[45]  H. Eisen,et al.  Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. , 1971, Proceedings of the National Academy of Sciences of the United States of America.